Chen, Wei http://orcid.org/0000-0002-7614-4436
Liu, Pingting http://orcid.org/0000-0003-1601-2818
Liu, Dong http://orcid.org/0000-0001-8941-0812
Huang, Haoliang
Feng, Xue
Fang, Fang
Li, Liang
Wu, Jian
Liu, Liang
Solow-Cordero, David E. http://orcid.org/0000-0002-9886-5058
Hu, Yang http://orcid.org/0000-0002-7980-1649
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY024932, EY023295, EY028106, EY032518, EY026877)
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
Glaucoma Research Foundation
BrightFocus Foundation
U.S. Department of Health & Human Services | NIH | National Eye Institute
Article History
Received: 23 November 2021
Accepted: 3 November 2022
First Online: 10 November 2022
Competing interests
: Y.H. is a consultant for Janssen BioPharma, Inc. A provisional patent application (Application number, US 63/284,424) has been filed through Stanford Office of Technology Licensing, titled “Neuroprotective agents for use in the treatment of optic neuropathies”, including HRH1 antagonists amoxapine, desloratadine, and maprotiline as potential neuroprotectants for the treatment of optic neuropathies. Yang Hu and Wei Chen are coinventors, and Stanford University as the applicant of this patent. The authors declare no other competing interests.